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Abstract Rheumatoid arthritis (Ra) is a systemic inflammatory connective 
tissue disease with polyarthritis as a prominent feature; however, extra-articular 
symptoms and signs are always present. advanced glycation end products with 
ability of cross-linking of proteins characteristic fluorescence and reaction 
with aGe-specific receptor RaGe (receptor for aGes). aGes action as well 
as aGe formation is directly related to both to inflammation and oxidative 
stress. RaGe is a 35-kDa polypeptide whose gene is located at the junction of 
the class II and III Hla regions on chromosome. aGe ligation of RaGe has 
been shown to activate p21ras and mitogen-activated protein (MaP) kinase, 
and stimulate nuclear translocation of the transcription factor NF-κB, thereby, 
resulting in the transcription of target genes thus may induce chronic cellular 
activation and tissue damage. 
Keywords: advance glycated end products, RaGe, Rheumatoid arthritis
1. IntRoductIon
Rheumatoid arthritis (Ra) is a systemic inflammatory connective tissue 
disease with polyarthritis as a prominent feature; however, extra-articular 
symptoms and signs are always present (Terao, et al., 2014; Megan, et 
al.,2014). It globally affects up to 0.5- 1% of the adult population, with 
survival rates comparable to coronary artery disease and cancer (Toshio, 
et al., 2013). Ra patients are two to five times more prone to the risk of 
coronary artery disease, silent myocardial ischemia, sudden cardiac death 
and overall cardiovascular (CV) mortality risk as compared to general 






Ra may act as independent risk for ischemic heart disease. about 50% of 
atherosclerotic coronary artery disease in community occurs in the absence 
of “traditional” CV risk factors, including male sex, family history for CV 
disease, age, dyslipidemia, arterial hypertension, diabetes mellitus, smoking 
and obesity (Rincon, et al., 2003)
Various factors predicting mortality in Ra patients includes:- a) Disease 
duration: If disease duration is more than 5 years then relative risk for mortality 
in Ra is 3.6 and mortality rate increases > 40% in next 5 years in Ra patients 
with extra-articular features present at baseline; b) Sex: Ra reduces life 
expectancy by approximately 7 years in men and 3 years in women in general 
but is more in older women; c) Treatment: Treatment with non steroidal anti-
inflammatory drugs (NSaIDs) increase 10% mortality in elderly due to risk 
of peptic ulcers. Glucocorticoids (dose < 7.5 mg/day) act as risk factor for 
myocardial infarction, cerebrovascular events and transient ischaemic attacks 
(arshad, et al., 2005).
although much new advancement in the treatment plan are available now 
and a lot of work is in progress, but still DMaRDs are the gold standard in the 
treatment of Rheumatoid arthritis. But the disease is not fully controllable even 
with various DMaRDs regimens. Triple drug regimen including combination of 
methotrexate + sulfasalazine + hydroxychloroquine has been used extensively 
by many rheumatologists since long (Saravanan, et al., 2002, Roberts, et al., 
2005), but even then many patients (≈ 25%) fail to respond adequately (O’Dell, 
et al., 1996). Response to even newly introduced biological DMaRDs like 
anti-TNF-alpha agents (Infliximab, etanercept, adalimumab) alone or in 
combination with conventional DMaRDs is also not complete (lipsky, et al., 
2000, Keystone, et al., 2004, Bathon, et al., 2000). Immune activity has to be 
controlled at various levels because many other pathways/ factors play role 
in Ra induced inflammation like advanced Glycation end Products (aGes), 
Matrix Metalloproteinases (MMPs), etc.
1.2 Advanced glycation end products
advanced glycation end products are represented by a heterogeneous group 
of compounds (e.g. pentosidine, carboxymethyllysine (CMl), imidazolone, 
etc.), some of them with characteristic fluorescence, ability of cross-linking of 
proteins and reaction with aGe-specific receptor RaGe (receptor for aGes) 
(Makita, et al., 1993, Horiuchi, et al., 2002). aGes formation as well as aGe 
action is linked both to oxidative stress and inflammation. apart from non-
enzymatic glycation, aGes can rise via autooxidation of sugars as well as 
other glycation intermediates—Schiff base and amadori products (Baynes, 
et al., 2000).
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Figure 1: Schematic representation of the formation of advanced glycation 
end products (aGes) through the Maillard reaction. Nonenzymatic reactions 
of the carbonyl groups of reducing sugars with primary amino groups of the 
proteins produce their corresponding Schiff bases, which undergo amadori 
rearrangements to give protein-derived aminomethyl ketones. Transition-
metal-ion-catalyzed glycoxidations of the amadori compounds, involving 
reactive oxygen species (ROS) and reactive nitrogen species (RNS), give 
1,2-dicarbonyl compounds such as glyoxal. Other sources of 1,2-dicarbonyl 
compounds include autoxidations of glucose, Schiff bases or the corresponding 
amadori products. These highly reactive dicarbonyl compounds further react 
with surrounding protein amino groups, and undergo further glycoxidations 






1.3 Formation of advanced glycation end products (AGEs) through the 
Maillard reaction 
The Maillard reaction is not actually a single reaction, but a series of nonenzymatic 
reactions involving the reaction between carbonyl groups of reducing-sugars 
with amino groups of proteins, enzymes, nucleic acids or phospholipids, 
forming Schiff bases and followed by their amadori rearrangement and 
subsequent oxidative modifications (glycoxidations) that are induced by 
reactive oxygen species (ROS) and reactive nitrogen species (RNS) (Reddy, 
 et al., 2006). The end result of these complex series of reactions is the formation 
of aGes. Glycoxidation of the amadori products, formed in the initial phase 
of the Maillard reaction, results in the formation of reactive 1,2-dicarbonyl 
compounds such as glyoxal and glucosone. autoxidations of glucose, or 
the corresponding Schiff base and the amadori products, also give rise to 
other 1,2-dicarbonylcompounds such as methylglyoxal, 1-deoxyglucosone 
(1-dG) and 3-deoxyglucosone (3-dG). The increased electrophilicity of these 
1,2-dicarbonyl compounds results in their relatively fast reactions with amino 
groups of proteins, and subsequent glycoxidative modifications result in the 
formation of the cross linked proteins (Figure 1). Some of the aGes are 
intensely colored compounds and have typical fluorescence characteristics 
(excitation at 330 nm and emission at 400 nm). However, not all of the aGes are 
derived from protein crosslinks. N-carboxymethyllysine (CMl), for example, 
is derived from the modification of a lysine residue of a single protein. Such 
protein modifications can cause enzymes inactivation. (Reddy, et al., 2006).
1.4 Receptor for advanced glycation end products
RaGe is a 35-kDa polypeptide whose gene is located at the junction of 
the class II and III Hla regions on chromosome. The proximity of cells 
expressing RaGe to lesions rich in aGes, and the activation that results, 
suggests that the aGe-RaGe interaction may trigger intracellular signal 
transduction mechanisms that alter properties of vascular and inflammatory 
effector cells. aGe ligation of RaGe has been shown to activate p21ras and 
mitogen-activated protein (MaP) kinase, and stimulate nuclear translocation 
of the transcription factor NF-κB, thereby, resulting in the transcription of 
target genes (lander, et al., 1997). ligation is believed to enhance receptor 
to as aGes. Pentosidine and N-carboxymethyllysine (CMl) can also be derived 
directly from the amadori products. Typically, the lysine and arginine residues 
of proteins are involved in the formation of the aGes, which, because of their 
involvement in enzyme active sites, can result in enzyme deactivation.
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expression and to initiate a positive feedback loop, in which receptor 
occupancy triggers increased RaGe expression, followed by further cellular 
activation. Ongoing expression of aGe on endothelium, smooth muscle cells, 
mononuclear phagocytes, and neurons when in close proximity to ligands, 
thus may induce chronic cellular activation and tissue damage (Schmidt, 
et al., 1999).
1.5 Receptor for advanced glycation end products in rheumatoid 
arthritis
The multi ligand receptor RaGe functions through amplification of various 
proinflammatory pathways when interacting with aGes that enhances the 
level of cytokines, adhesion molecule and vascular cell expression. (Yaw 
Kuang chuah, et al., 2013). (Basta, et al., 2002). In inflamed Ra joints, 
levels of High Mobility Group Box chromosomal protein-1 (HMGB-1) and 
S100a12, as well as those of aGes, are strikingly increased (Kokkola, et 
al., 2002, Miyata, et al., 1998). High levels of RaGe and proinflammatory 
adhesion molecules are found to be expressed in the Ra synovial tissue 
(ST) endothelium (Basta, et al., 2002). In addition, macrophages established 
from Ra synovial fluid (SF) cells contain large amounts of RaGe protein 
(Taniguchi, et al., 2003) in Ra, targeted site i.e synovial tissue is infiltrated 
by various inflammatory mediator that is characterized by presence of 
CD68+ macrophages on RaGe antigen and along with this the level of 
TNFα, cytokine and Il-1 increased at of the inflammatory site which leads 
to progression of disease. (Hou, et al., 2002, Yaw Kuang chuah, et al., 
2013). It was shown in a study that RaGe-inducing factors were secreted 
spontaneously from Ra synovial tissue cells, and RaGe mRNa expression 
in monocytes was initiated by various cytokines, including the two essential 
proinflammatory cytokines, Il-1β and TNF, the Th1 cytokine IFNγ, and, of 
interest, the antiinflammatory cytokine Il-10 (Iwahashi, et al., 2004). Studies 
of the RaGe gene have identified the presence of at least two functional NF-
κB sites in the promoter gene (li, et al., 1997), and RaGe expression is 
thereby regulated at the transcriptional level by NF-κB activation (li, et al., 
1997, Tanaka, et al., 2000). The NF-κB pathway is believed to play a key 
role in RaGe induction by both RaGe ligands and the proinflammatory 
cytokines Il-1 and TNF-. These cytokines also stimulate HMGB-1 and 
S100a12 secretion from macrophages and neutrophils (Kokkola, et al., 
2002, Taniguchi, et al., 2003. (Hofmann, et al., 1997). There seems to be 
an intimate relationship between the RaGe–ligand system and the cytokine 
cascade in Ra, forming a positive feedback loop that leads to the propagation 






2. RolE oF AGEs In RhEuMAtoId ARthRItIs
It is now proved that Rheumatoid arthritis generates aGes, as a byproduct of 
oxidative stress, in addition to other RaGe ligands as a result of neutrophils 
activation. The role of RaGe and its ligands in the pathogenesis of inflammatory 
joint disease has been studied in a murine model of inflammatory arthritis, 
in which blockade of RaGe suppressed clinical and histological evidence of 
arthritis (Hofmann, et al., 2002). aGes have been shown to accumulate in 
inflamed Ra synovial tissue with RaGe antigen expression overlapping with 
the distribution of aGe epitopes (Basta, et al., 2002). However, in a small 
study looking at RaGe staining patterns of synovial tissue, there were no 
differences has been seen in staining pattern between those patients with Ra 
and those with osteoarthritis (Drinda, et al., 2005).
Ra is a chronic systemic disease, although its major clinical consequence 
is inflammation of the joints and contiguous structures. It is shown in a study 
that pentosidine is supposed to play an important role in Ra (Chen, et al., 
1999). Pentosidine level elevated in serum and urine reflects the increased 
disease activity of Ra (Takahashi, et al., 1997). In a study of 20 patients, 
pentosidine levels in serum and synovial fluid were found to be significant 
higher in Ra than Oa patients. Moreover, this was significantly correlated with 
CRP, eSR and lansbury Index (lI). When pentosidine was compared between 
subgroups of Ra patients who were divided into high (CRP >20mg/l and lI > 
40%) and low (CRP<20mg/l and lI < 20%) activity groups, it was found that 
pentosidine levels in serum and synovial fluid were significantly higher in high 
activity group. The levels of pentosidine were found higher in patients with 
active Ra than in those with inactive Ra because serum and urine levels of 
pentosidine are found to be correlated with the activity of Ra, thus serum and 
urinary pentosidine may be act as significant and novel marker for evaluating 
the disease status and the activity of Ra (Takahashi, et al., 1997). 
CMl is an aGe, which can be used as a marker of oxidative stress 
(Nerlich, et al., 1999, Nakayama, et al., 1999). In Ra, inflammatory changes 
and destruction of joints are seen (ames, et al., 1999). The accumulation of 
CMl in Ra synovial tissue might be the result of oxidative stress during local 
and systemic inflammation. Oxidative stress can cause different “metabolic 
changes”, leading to the mutation of key regulatory genes. This may help to 
transform inflammation into chronic disease (Tak, et al., 2000). a study showed 
that in older patients aGes represent new epitopes and contain new antigenic 
structures (yang, et al., 1994), thereby possibly contributing to the generation 
of autoimmune responses (Michaelsson, et al., 1996). This theory is supported 
by the findings of Miyata et al., 1998 and Takahashi et al, 1997, who found 
a correlation between the inflammatory activity and concentration of aGes 
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measured in the urine and blood of patients with Ra. Pentosidine formation 
is accelerated by oxidative conditions, thus pentosidine is supposed to be 
implicated in the disease process of Ra. It was demonstrated in a study, that 
pentosidine levels were elevated in cartilage and suggested that oxidative stress 
was related to the elevation of pentosidine in the cartilage of Ra (Takahashi, 
et al., 1994). It was shown by Takahashi, et al. in a study that Serum levels 
of pentosidine in Ra (mean 150.1 nmol/l) were significantly higher than in 
controls patients (mean 81.7 nmol/l). urinary levels of pentosidine in Ra (10.7 
μmol/mol creatinine) were significantly higher than in controls (3.8μmol/mol 
creatinine). Serum and urinary pentosidine were significantly related with age 
in Ra, although they were not related with age in controls. In another study, it 
was shown that the conc. of pentosidine in Ra patients is seen to be as high as 
≈ 850 nmol/l as compared to ≈ 100 nmol/l in control group. On the other hand 
the conc. of pentosidine is seen to be ≈ 280 nmol/l and ≈ 300 nmol/l in diabetes 
and Sle patient groups, respectively, when compared with control groups (≈ 
100nmol/l) (Rodriguez, et al., 1997).
These findings implicate aGes as possible key players in the development 
of Rheumatoid arthritis disease and its complications.
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